Crossmark

Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s12951-026-04628-3

Published Online: 2026-06-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Romano, Miriam https://orcid.org/0000-0002-3972-460X
Musicò, Angelo https://orcid.org/0000-0001-6193-4366
Tassoni, Selene https://orcid.org/0009-0002-4117-6662
Paolini, Lucia https://orcid.org/0000-0002-4410-5272
Zendrini, Andrea https://orcid.org/0000-0002-3626-0360
Gilberti, Enrica

Orlandi, Francesca

Pedrazzi, Tatiana

Alacqua, Silvia https://orcid.org/0000-0003-2611-1844
Segala, Agnese https://orcid.org/0000-0002-9744-4681
Zenatelli, Rossella https://orcid.org/0000-0002-7743-0397
Cifola, Ingrid https://orcid.org/0000-0003-2819-1171
Mangano, Eleonora https://orcid.org/0000-0002-4040-4654
Consolandi, Clarissa https://orcid.org/0000-0002-9328-9557
Camboni, Tania

Signati, Lorena https://orcid.org/0000-0001-7695-3471
Mazzucchelli, Serena https://orcid.org/0000-0001-6904-8895
Neva, Arabella https://orcid.org/0000-0002-2593-3785
Ragni, Maurizio https://orcid.org/0000-0001-6548-741X
Severgnini, Marco https://orcid.org/0000-0001-8655-1206
Valerio, Alessandra https://orcid.org/0000-0001-5844-2256
Pomarico, Giuseppe https://orcid.org/0000-0003-3029-7063
Almici, Camillo https://orcid.org/0000-0002-9438-2569
De Palma, Giuseppe

Corsi, Fabio https://orcid.org/0000-0002-6469-4086
Bergese, Paolo https://orcid.org/0000-0002-4652-2168
Radeghieri, Annalisa https://orcid.org/0000-0003-2737-1090
Funding

Funding for this research was provided by:

Horizon 2020 Framework Programme (952183)

PNRR-HEAL ITALIA – Spoke 5 – Next Gen Therapeutics (ORGANO-CAR)

Ministero dell'Università e della Ricerca (PRIN 2017E3A2NR_004)
License Information

Text and Data Mining valid from 2026-06-07

Version of Record valid from 2026-08-13
More Information

Article History

Received: 14 January 2026

Accepted: 25 May 2026

First Online: 7 June 2026

Declarations

Ethics approval and consent to participate: Research was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and Good Clinical Practice. The study was approved by the ethics committee of Spedali Civili di Brescia (Protocol number 5705). Patient derived organoids were obtained by Bruno Boerci Oncological Biobank, (ICS Maugeri IRCCS’s ethical committee approvation of 27 July 2009).

Patient consent: Informed consent was obtained from all the subjects enrolled in the study. The privacy rights of subjects involved in the study have always been observed.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below